A Multi-center Study of the Treatment Patterns and Clinical Outcomes of Subsequent Therapies After Progression on Palbociclib in HR+/HER2- Metastatic Breast Cancer
Latest Information Update: 02 Nov 2021
At a glance
- Drugs Palbociclib (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- 01 Aug 2021 Status changed from active, no longer recruiting to completed.
- 20 Aug 2020 New trial record